<DOC>
	<DOCNO>NCT00360347</DOCNO>
	<brief_summary>This study investigate efficacy , safety pharmacokinetics Mircera adult anemic patient multiple myeloma . In first stage study , patient randomize receive subcutaneous injection Mircera every 3 week , dose 2.0 , 3.5 5.0 micrograms/kg . Following administration 2 dos , evaluation hemoglobin increase make week 6 . In second stage , group patient receive additional dos Mircera , dose 1.0 , 6.5 8.0 micrograms/kg , depend efficacy , safety pharmacokinetic considerations.The anticipated time treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Mircera Anemic Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; confirm diagnosis multiple myeloma ; anemia ( hemoglobin &lt; =11g/dL screen visit ) . transfusion red blood cell 2 month prior first plan dose study medication ; therapyresistant hypertension ; relevant acute chronic bleeding within 3 month prior plan start study treatment ; recombinant human erythropoietin erythropoiesisstimulating drug therapy within 3 month prior plan start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>